Oxford Cancer Biomarkers

Oxford Cancer Biomarkers is a company dedicated to pioneering precision medicine by translating scientific discoveries into predictive biomarker diagnostic products. Founded in 2010 by Dr. Nick La Thangue, Chair of Cancer Biology at Oxford University, and Prof. David Kerr, Professor of Cancer Medicine at Oxford University, the company has strong ties with the University of Oxford and the Medical Sciences Division. Its investors include Longwall Venture Partners LLP, Esperante BV, Ningbo My-BioMed Biotechnology Co.,Ltd., CancerRop Co. Ltd., and the University of Oxford, with a recent £1.48M grant investment from NHS England. Oxford Cancer Biomarkers focuses on the biopharma, biotechnology, and healthcare industries, with a range of predictive biomarkers aimed at enabling personalized care for colorectal cancer patients. Its flagship product, ToxNav, is the first 20 SNP germline assay designed to predict life-threatening adverse reactions from chemotherapy. In addition, the company has launched OncoProg, a digital pathology test for tumor recurrence in China and is collaborating with academic partners to develop a population-based genome test for lifetime colorectal cancer risk assessment. In summary, Oxford Cancer Biomarkers, with its strong scientific foundation and strategic partnerships, is poised to make a significant impact in advancing personalized cancer treatment through predictive biomarker diagnostics.